{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:13:08Z","timestamp":1783710788707,"version":"3.55.0"},"reference-count":22,"publisher":"Xia & He Publishing","issue":"XX","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,22]]},"DOI":"10.14218\/jcth.2016.00060","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T20:37:39Z","timestamp":1487709459000},"page":"1-4","source":"Crossref","is-referenced-by-count":4,"title":["Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience"],"prefix":"10.14218","volume":"XX","author":[{"given":"Avin","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Perumpail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Cholankeril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami J.","family":"Daugherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex S.","family":"Lapasaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"key20170221203733_b1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tid.12348","article-title":"Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis","volume":"17","author":"Perumpail","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"key20170221203733_b2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10620-015-3756-z","article-title":"A new standard of care? standard dose sofosbuvir in an HCV-infected liver transplant recipient undergoing hemodialysis","volume":"61","author":"Perumpail","year":"2016","journal-title":"Dig Dis Sci"},{"key":"key20170221203733_b3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.22545","article-title":"Treatment of chronic hepatitis C in hemodialysis patients","volume":"48","author":"Berenguer","year":"2008","journal-title":"Hepatology"},{"key":"key20170221203733_b4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","article-title":"Hepatitis C infection and the patient with end-stage renal disease","volume":"36","author":"Fabrizi","year":"2002","journal-title":"Hepatology"},{"key":"key20170221203733_b5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/sdi.12292","article-title":"What are the management issues for hepatitis C in dialysis patients?: natural history of hepatitis C in dialysis populations","volume":"27","author":"Carrion","year":"2014","journal-title":"Semin Dial"},{"key":"key20170221203733_b6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1525-139X.2005.18108.x","article-title":"National surveillance of dialysis-associated diseases in the United States, 2002","volume":"18","author":"Finelli","year":"2005","journal-title":"Semin Dial"},{"key":"key20170221203733_b7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1525-139X.2007.00311.x","article-title":"Hepatitis C virus infection and the dialysis patient","volume":"20","author":"Fabrizi","year":"2007","journal-title":"Semin Dial"},{"key":"key20170221203733_b8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"key":"key20170221203733_b9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","article-title":"Treatment of hepatitis C virus infection in patients with end-stage renal disease","volume":"26","author":"Liu","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"key20170221203733_b10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1572-0241.2008.01981.x","article-title":"HCV in patients with end-stage renal disease","volume":"103","author":"Okoh","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key20170221203733_b11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000355803","article-title":"Recent advances on hepatitis C virus in dialysis population","volume":"39","author":"Fabrizi","year":"2014","journal-title":"Kidney Blood Press Res"},{"key":"key20170221203733_b12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2012.10.009","article-title":"Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?","volume":"56","author":"Dumortier","year":"2013","journal-title":"J Clin Virol"},{"key":"key20170221203733_b13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/L14-5008-3","article-title":"Triple therapy for hepatitis C virus infection in patients receiving hemodialysis","volume":"160","author":"Lemoinne","year":"2014","journal-title":"Ann Intern Med"},{"key":"key20170221203733_b14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"key":"key20170221203733_b15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/17512433.2015.1086266","article-title":"Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?","volume":"8","author":"Fabrizi","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key20170221203733_b16","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/S0168-8278(12)61113-1","article-title":"The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977","volume":"56","author":"Cornpropst","year":"2012","journal-title":"J Hepatol"},{"key":"key20170221203733_b17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"key":"key20170221203733_b18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"key":"key20170221203733_b19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"key20170221203733_b20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"key20170221203733_b21","doi-asserted-by":"crossref","first-page":"171537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"key20170221203733_b22","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S0168-8278(15)30147-1","article-title":"Safety of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 Study","volume":"62","author":"Pockros","year":"2015","journal-title":"J Hepatol"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/ArticleFullText.aspx?sid=2&jid=1&id=10.14218\/JCTH.2016.00060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:16:41Z","timestamp":1783707401000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/ArticleFullText.aspx?sid=2&jid=1&id=10.14218\/JCTH.2016.00060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":22,"journal-issue":{"issue":"XX","published-online":{"date-parts":[[2017,2,22]]},"published-print":{"date-parts":[[2017,2,22]]}},"alternative-id":["10.14218\/JCTH.2016.00060"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2016.00060","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]}}}